{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:58:59Z","timestamp":1756994339595},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In childhood, movement disorders are generated by a very large number of disorders of the nervous system, and the very different developmental ages at which these occur make studies of pharmacotherapy efficacy extremely difficult. In most clinical practices, medication used in management is by trial and error, and limited by lack of efficacy and\/or adverse drug reactions leading to drug intolerance. Nevertheless, symptom reduction using polypharmacy must be balanced against any accompanying comorbidities such as poor attention and concentration, constipation, ileus, urinary retention, blurred vision sedation and respiratory depression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A \u2018personalised medicine\u2019 approach may lead to specific management breakthroughs that are beneficial to a wider number of children. At present, neuromodulation with implantable devices offers greater proven efficacy for dystonia, myoclonus and dystonic-choreoathetosis, but enteral, intravenous and, more recently, transdermal medication strategies with clonidine patches and enteral gabapentin may provide important relief for both home management and critical care settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The current review brings the clinician up-to-date with the latest, albeit limited, thinking on the pharmacological management of movement disorders in children by focussing on goal-directed outcome measures to improve clinical decision-making in an evidence-light clinical setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000555","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T23:19:55Z","timestamp":1507072795000},"page":"652-664","source":"Crossref","is-referenced-by-count":3,"title":["Advances in pharmacotherapies for movement disorders in children: current limitations and future progress"],"prefix":"10.1097","volume":"29","author":[{"given":"Jean-Pierre","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231208","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1474-4422(16)00132-0","article-title":"Advances in management of movement disorders in children","volume":"15","author":"Koy","year":"2016","journal-title":"Lancet Neurol"},{"key":"R2-20231208","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/WCO.0000000000000214","article-title":"A field guide to current advances in paediatric movement disorders","volume":"28","author":"Silveira-Moriyama","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"R3-20231208","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrneurol.2015.172","article-title":"Monoamine neurotransmitter disorders \u2013 clinical advances and future perspectives","volume":"11","author":"Ng","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"R4-20231208","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1212\/WNL.0000000000003897","article-title":"l-Dopa in dystonia: a modern perspective","volume":"88","author":"Maas","year":"2017","journal-title":"Neurology"},{"key":"R5-20231208","doi-asserted-by":"crossref","first-page":"15082","DOI":"10.1038\/nrdp.2015.82","article-title":"Cerebral palsy","volume":"2","author":"Graham","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20231208","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov Disord"},{"key":"R7-20231208","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.parkreldis.2016.10.001","article-title":"Classification of dystonia in childhood","volume":"33","author":"Lumsden","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"R8-20231208","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/jnnp-2013-307041","article-title":"The impact and prognosis for dystonia in childhood including dystonic cerebral palsy: a clinical and demographic tertiary cohort study","volume":"85","author":"Lin","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-20231208","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejpn.2016.02.006","article-title":"Progression to musculoskeletal deformity in childhood dystonia","volume":"20","author":"Lumsden","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"R10-20231208","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejpn.2015.01.003","article-title":"Interventional studies in childhood dystonia do not address the concerns of children and their carers","volume":"19","author":"Lumsden","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"R11-20231208","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ejpn.2016.02.003","article-title":"Medication use in childhood dystonia","volume":"20","author":"Lumsden","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"R12-20231208","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/dmcn.12108","article-title":"Dystonia Severity Action Plan: a simple grading system for medical severity of status dystonicus and life-threatening dystonia","volume":"55","author":"Lumsden","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"R13-20231208","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejpn.2015.09.007","article-title":"Gabapentin can significantly improve dystonia severity and quality of life in children","volume":"20","author":"Liow","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"R14-20231208","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ejpn.2017.03.001","article-title":"Clonidine use in the outpatient management of severe secondary dystonia","volume":"21","author":"Sayer","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"R15-20231208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2017.07.007","article-title":"Safety and efficacy of high-dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: an illustrative case-series","author":"Nakou","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"R16-20231208","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.35.1.73","article-title":"Validity and reliability of a rating scale for the primary torsion dystonias","volume":"35","author":"Burke","year":"1985","journal-title":"Neurology"},{"key":"R17-20231208","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","article-title":"Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl","volume":"36","author":"Burke","year":"1986","journal-title":"Neurology"},{"key":"R18-20231208","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1469-8749.2009.03581.x","article-title":"Rating scales for dystonia in cerebral palsy; reliability and validity","volume":"52","author":"Monbaliu","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"R19-20231208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/dmcn.12965","article-title":"Burke\u2013Fahn\u2013Marsden dystonia severity, gross motor, manual ability, and communication function classification scales in childhood hyperkinetic movement disorders including cerebral palsy: a \u2018Rosetta Stone\u2019 study","volume":"58","author":"Elze","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"R20-20231208","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1469-8749.2012.04312.x","article-title":"Inter-relationships of functional status in cerebral palsy; analyzing gross motor function, manual ability, and communication function classification systems in children","volume":"54","author":"Hidecker","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"R21-20231208","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1469-8749.2008.03141.x","article-title":"Validity and reliability of the guidelines of the surveillance of cerebral palsy in Europe for the classification of cerebral palsy","volume":"50","author":"Gainsborough","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"R22-20231208","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-8749.2010.03843.x","article-title":"The contribution of spasticity to the movement disorder of cerebral palsy using pathway analysis: does spasticity matter?","volume":"53","author":"Lin","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"R23-20231208","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fneur.2016.00226","article-title":"Recognizing the common origins of dystonia and the development of human movement: a manifesto of unmet needs in isolated childhood dystonias","volume":"7","author":"Lin","year":"2016","journal-title":"Front Neurol"},{"key":"R24-20231208","first-page":"1","article-title":"Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay","author":"Saitsu","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R25-20231208","first-page":"1","article-title":"Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation","author":"Kulkarni","year":"2015","journal-title":"J Child Neurol"},{"key":"R26-20231208","article-title":"GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS","author":"Waak","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R27-20231208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ng.3740","article-title":"Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia","volume":"49","author":"Meyer","year":"2017","journal-title":"Nat Genet"},{"key":"R28-20231208","first-page":"185","article-title":"Pathophysiology of spasticity and clinical experience with baclofen","author":"Lance","year":"1980","journal-title":"Spasticity: disordered motor control"},{"key":"R29-20231208","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/ene.13322","article-title":"European consensus on the concepts and measurement of the pathophysiological neuromuscular responses to passive muscle stretch","volume":"24","author":"van den Noort","year":"2017","journal-title":"Eur J Neurol"},{"key":"R30-20231208","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1542\/peds.2005-3016","article-title":"Definition and classification of negative motor signs in childhood","volume":"118","author":"Sanger","year":"2006","journal-title":"Pediatrics"},{"key":"R31-20231208","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/mds.23088","article-title":"Definition and classification of hyperkinetic movements in childhood","volume":"25","author":"Sanger","year":"2010","journal-title":"Mov Disord"},{"key":"R32-20231208","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-017-0243-3","article-title":"Clinical management of dystonia in childhood","author":"Luc","year":"2017","journal-title":"Paediatr Drugs"},{"key":"R33-20231208","article-title":"Treatable inherited rare movement disorders","author":"Jinnah","year":"2017","journal-title":"Mov Disord"},{"key":"R34-20231208","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2007.03.005","article-title":"Functional biology of the alpha (2)delta subunits of voltage-gated calcium channels","volume":"28","author":"Davies","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"R35-20231208","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cell.2009.09.025","article-title":"Gabapentin receptor \u03b12\u03b4-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis","volume":"139","author":"Eroglu","year":"2009","journal-title":"Cell"},{"key":"R36-20231208","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"R37-20231208","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003088-198814050-00002","article-title":"Clinical pharmacokinetics of clonidine","volume":"14","author":"Lowenthal","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"R38-20231208","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1460-9592.2006.02185.x","article-title":"Effects of preanesthetic administration of midazolam, clonidine, or dexmedetomidine on postoperative pain and anxiety in children","volume":"17","author":"Schmidt","year":"2007","journal-title":"Paediatr Anaesth"},{"key":"R39-20231208","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00134-004-2319-0","article-title":"Use of oral clonidine for sedation in ventilated paediatric intensive care patients","volume":"30","author":"Arenas-Lopez","year":"2004","journal-title":"Intensive Care Med"},{"key":"R40-20231208","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01705163","article-title":"Clonidine as a sedative adjunct in intensive care","volume":"16","author":"Bohrer","year":"1990","journal-title":"Intensive Care Med"},{"key":"R41-20231208","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1542\/peds.2010-1260","article-title":"Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD","volume":"127","author":"Kollins","year":"2011","journal-title":"Pediatrics"},{"key":"R42-20231208","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/adc.2007.128728","article-title":"When to use drugs to help sleep","volume":"93","author":"Gringras","year":"2008","journal-title":"Arch Dis Child"},{"key":"R43-20231208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/070674371205700302","article-title":"Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy","volume":"57","author":"Pringsheim","year":"2012","journal-title":"Can J Psychiatry"},{"key":"R44-20231208","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment","volume":"20","author":"Roessner","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R45-20231208","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejpn.2011.04.005","article-title":"Movement disorder emergencies in childhood","volume":"15","author":"Kirkham","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"R46-20231208","doi-asserted-by":"crossref","first-page":"965932","DOI":"10.1155\/2012\/965932","article-title":"Paroxysmal autonomic instability with dystonia after pneumococcal meningoencephalitis","volume":"2012","author":"Safadieh","year":"2012","journal-title":"Case Rep Med"},{"key":"R47-20231208","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/7010.2006.00134","article-title":"Oral baclofen and clonidine for treatment of spasticity in children","volume":"21","author":"Lubsch","year":"2006","journal-title":"J Child Neurol"},{"key":"R48-20231208","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1474-4422(17)30252-1","article-title":"Clinical presentation and management of dyskinetic cerebral palsy","volume":"16","author":"Monbaliu","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201712000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T05:01:52Z","timestamp":1702011712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201712000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000555","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}